15 July 2025

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

Trading Update and Notice of Results 

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a trading update for the six months ended 30 June 2025.

Key financial highlights*:

·      Gross revenue +33% to £1.34m (H1 2024: £1.01m)

·      Gross profit +33% to £748,000 (H1 2024: £564,000)

·      EBITDA loss significantly reduced by 59% to £110,000 (H1 2024: £268,000 loss)

·      Strong cash balance of £1.3m (H1 2024: £865,000)

·      Current order book at record level which augurs well for H2

*Numbers are from unaudited management accounts

ProBiotix has delivered a solid performance in the first six months of 2025 with all our key financial metrics ahead of budget, largely driven by increasing demand and awareness of our products. Maintaining the gross profit margin at 55%, despite currency fluctuations, including the weakening of the Dollar against Sterling, is also a pleasing result.

During the period our partnership agreement with Kemin China Technology Co. Ltd has developed well, with the first orders now delivered and further repeat sales expected. We are also gaining traction with our recently announced partnership with TopHealth in South Korea, which has been buoyed by a product launch of CholBiome X₃ by leading pharmacy influencer network PBros, which should augment further growth in the country. Additional products are planned for 2026.

In Greece, in collaboration with the Company's own scientific team, our partner, Eifron SA  launched its cardiometabolic product Beiofolac Cholesterol with key opinion leaders at the Panhellenic Congress of General Medicine in Greece in late April; this has helped boost awareness of Beiofolac Cholesterol and sales are now gaining significant traction.

Our business in the US continues to move apace. The leading brand, Life Extension®, launched its LP_LDL® based "young gut" product online and nationwide across a number of drugstore chains, in June. Our key partner, Seed, has expanded the commercial reach of its products to new sales outlets, a move which should drive further orders.

Notice of Results

ProBiotix will release its interim results for the six months to 30 June 2025 on Monday, 8 September 2025.

Steen Andersen, CEO of ProBiotix, commented: "We are delighted with our first half performance, which continues to demonstrate strong momentum in the business, and leaves us well placed to continue our growth throughout the rest of the current financial year and beyond.

We continue to innovate, as evidenced by the launch of two new menopause-focused women's health concepts at the recent Vitafoods Nutraceutical Trade Show in Barcelona. Based on LP_LDL®, the new products have gained positive feedback, with several commercial projects already initiated with customers.

Global demand for probiotics continues to grow, largely driven by a combination of lifestyle, health and demographic factors. Set against this, we enter the second half of the year with a strong pipeline of new business opportunities, a record order book and a balance sheet which can fully fund our growth aspirations."

For further information, please contact:

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.